All PlansCoverageLow impact
Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients With Cancer
Blue Cross & Blue Shield of Mississippi·MS · Oncology·Medical Policy
Effective date
Apr 17, 2025
We identified it
Jun 20, 2026
Summary
This policy confirms that laboratory testing for 5-fluorouracil dosing optimization (area under curve analysis) and genetic testing for DPYD/TYMS gene variants to guide 5-fluorouracil chemotherapy dosing remain investigational and not covered. No changes were made to the existing policy.
Action Required
No action required - this is a policy review with no changes. Continue to treat CPT codes 81232, 81346, 84999 and HCPCS S3722 as investigational/non-covered for 5-fluorouracil chemotherapy optimization. Claims for these codes related to cancer treatment dosing will be denied.